Shots:
Health Canada has approved Gazyva (obinutuzumab) for adults with active lupus nephritis receiving standard therapy
Approval was based on P-II (NOBILITY) & P-III (REGENCY) trials, where in REGENCY (n=271), 46.4% on Gazyva + SoC achieved CRR vs 33.1% on SoC. Gazyva’s safety profile was consistent with its well-established profile from haematology-oncology indications
Gazyva is…
